A 52-week pilot study of the effects of exenatide on body weight in patients with hypothalamic obesity.

Lomenick JP, Buchowski MS, Shoemaker AH

Obesity (Silver Spring, Md.)2 May 2016Cited by 49 (Europe PMC)

PMID27133664PMCIDPMC4882247DOI10.1002/oby.21493PepBankPUB-27133664

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In adults with hypothalamic obesity, weight change during exenatide therapy was not significant compared with baseline.
In plain wordsIn adults with hypothalamic obesity, weight did not change significantly from baseline during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeMean weight change
Study
n = 8
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
10 mcg b.i.d. · 52 weeksAs given in this study (human).
Measurements
Weight change
−1.4 kg
exenatide therapy
Source sentences
Summary
Change in weight with exenatide therapy was not significant (-1.4 ± 4.3 kg [95% CI -4.9 to 2.2], P = 0.40), but six out of eight completers lost weight (-6.2 to -0.2 kg).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a prospective, open-label, 52-week pilot study of exenatide (10 mcg b.i.d.) in adults with HO.
Summary · context
Ten patients enrolled, and eight completed the study.
Report a problemFND-2713366402
02HumanNon-randomized trialEfficacy outcome
In adults with hypothalamic obesity, six of eight exenatide completers lost weight compared with baseline.
In plain wordsSix of eight adults with hypothalamic obesity who completed exenatide treatment lost weight from baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseCompleters with weight loss
Study
n = 8
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
10 mcg b.i.d. · 52 weeksAs given in this study (human).
Measurements
Completers with weight loss
6 patients
eight completers
Weight loss range
−6.2 to −0.2 kg
completers losing weight
Source sentences
Summary
Change in weight with exenatide therapy was not significant (-1.4 ± 4.3 kg [95% CI -4.9 to 2.2], P = 0.40), but six out of eight completers lost weight (-6.2 to -0.2 kg).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a prospective, open-label, 52-week pilot study of exenatide (10 mcg b.i.d.) in adults with HO.
Summary · context
Ten patients enrolled, and eight completed the study.
Report a problemFND-2713366403
03HumanNon-randomized trialEfficacy outcome
In adults with hypothalamic obesity, reported food intake decreased during exenatide treatment compared with baseline.
In plain wordsAdults with hypothalamic obesity reported lower food intake during exenatide treatment than at baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFood recall intake
Study
n = 8
Comparator
Baseline
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
10 mcg b.i.d. · 52 weeksAs given in this study (human).
Measurements
Food recall intake at baseline
7837.8 kJ
baseline
Food recall intake during treatment
6258.4 kJ
exenatide treatment
Source sentences
Summary
Participants reported significantly lower intake on food recall during treatment compared with baseline (7837.8 ± 2796.6 vs. 6258.4 ± 1970.7 kJ [95% CI -2915.8 to -242.6], P = 0.027), but there was no change in intake during buffet meals.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a prospective, open-label, 52-week pilot study of exenatide (10 mcg b.i.d.) in adults with HO.
Summary · context
Ten patients enrolled, and eight completed the study.
Report a problemFND-2713366404
04HumanNon-randomized trialEfficacy outcome
In adults with hypothalamic obesity, buffet meal intake did not change during exenatide treatment compared with baseline.
In plain wordsBuffet meal intake did not change from baseline during exenatide treatment in adults with hypothalamic obesity.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeBuffet meal intake
Study
n = 8
Comparator
Baseline
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
10 mcg b.i.d. · 52 weeksAs given in this study (human).
Source sentences
Summary
Participants reported significantly lower intake on food recall during treatment compared with baseline (7837.8 ± 2796.6 vs. 6258.4 ± 1970.7 kJ [95% CI -2915.8 to -242.6], P = 0.027), but there was no change in intake during buffet meals.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a prospective, open-label, 52-week pilot study of exenatide (10 mcg b.i.d.) in adults with HO.
Summary · context
Ten patients enrolled, and eight completed the study.
Report a problemFND-2713366405
05HumanNon-randomized trialSafety outcome
In adults with hypothalamic obesity, exenatide therapy was well tolerated.
In plain wordsAdults with hypothalamic obesity tolerated exenatide well.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableTolerability
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
10 mcg b.i.d. · 52 weeksAs given in this study (human).
Source sentences
Summary
Exenatide therapy was well tolerated.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a prospective, open-label, 52-week pilot study of exenatide (10 mcg b.i.d.) in adults with HO.
Summary · context
Ten patients enrolled, and eight completed the study.
Report a problemFND-2713366401

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT01484873

Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor

Vanderbilt University Medical Centern = 10Jun 2012 to Mar 2015

Obesity · Overweight · Craniopharyngioma

Trial page ClinicalTrials.govUpdated 3 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.